Metocard-CHT 50 Tablet ER is a combination antihypertensive medication containing Chlorthalidone (12.5 mg), Metoprolol Succinate (50 mg), and Telmisartan (40 mg). This formulation is designed for extended-release administration to provide sustained blood pressure control in patients with hypertension. Chlorthalidone, a thiazide-like diuretic, promotes sodium and water excretion, reducing plasma volume and peripheral vascular resistance. Metoprolol Succinate, a selective beta-1 adrenergic receptor blocker, decreases heart rate, myocardial contractility, and cardiac output, thereby lowering blood pressure and reducing cardiac workload. Telmisartan, an angiotensin II receptor blocker (ARB), inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation and decreased blood pressure. The combination of these agents offers complementary mechanisms to achieve effective antihypertensive control, particularly in patients requiring multiple drug therapy. Metocard-CHT 50 Tablet ER is indicated for the management of essential hypertension and can help reduce the risk of cardiovascular events such as stroke and myocardial infarction. It should be used under medical supervision, with monitoring of blood pressure, renal function, and electrolytes to minimize potential adverse effects including hypotension, electrolyte imbalance, bradycardia, and renal impairment.